BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company. It develops immuno-oncology cancer therapies and offers a drug development pipeline which includes a variety of Plinabulin products. The company also provides a preclinical immuno-oncology pipeline that includes BPI-002, BPI-003, and BPI-004 programs.
Type | Public | |
Founded | 2010 | |
HQ | New York, NY, US | Map |
Website | beyondspringpharma.com | |
Employee Ratings | More |
USD | |
---|---|
Net income (FY, 2019) | (40.3m) |
EBIT (FY, 2019) | (40.3m) |
Market capitalization (6-Jan-2021) | 478.3m |
Closing stock price (6-Jan-2021) | 12.2 |
Cash (31-Dec-2019) | 35.9m |
EV | 446.3m |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.0m | 2.8m | 3.3m | 728.0k | 1.4m | 1.5m | 1.6m | 2.1m | 2.5m |
R&D expense | 46.7m | 12.2m | 15.3m | 14.1m | 11.0m | 14.1m | 6.3m | 5.2m | 7.2m |
Operating expense total | 47.8m | 15.0m | 18.6m | 14.8m | 12.4m | 15.7m | 8.0m | 7.3m | 9.7m |
EBIT | (47.8m) | (15.0m) | (18.6m) | (14.8m) | (12.4m) | (15.7m) | (7.7m) | (7.3m) | (9.7m) |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|
Cash | 54.6m | 49.0m | 37.7m | 18.4m | 19.4m | 12.8m | 2.0m | 674.0k | 24.7k |
Prepaid Expenses | 131.0k | 338.0k | 236.0k | 284.0k | 525.0k | 473.0k | 150.0k | 167.0k | 362.0 |
Current Assets | 55.7m | 50.8m | 43.2m | 23.3m | 24.8m | 15.2m | 3.6m | 2.0m | 30.2k |
PP&E | 88.0k | 87.0k | 126.0k | 124.0k | 116.0k | 191.0k | 263.0k | 237.0k | 217.0 |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2019 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | 47.7m | (62.6m) | (80.1m) | (14.1m) | (26.9m) | (42.8m) | (7.8m) | (15.4m) | (25.3m) |
Depreciation and Amortization | 6.0k | 13.0k | 22.0k | 12.0k | 20.0k | 29.0k | 23.0k | 41.0k | 61.0k |
Accounts Payable | 568.0k | 1.6m | 581.0k | 1.0m | (575.0k) | (18.0k) | (620.0k) | (1.1m) | (7.6m) |
Cash From Operating Activities | (5.3m) | (10.4m) | (18.6m) | (8.9m) | (22.0m) | (31.6m) | (5.1m) | (13.1m) | (35.5m) |
USD | FY, 2016 |
---|---|
Financial Leverage | 1.2 x |
Company Name | Date | Deal Size |
---|---|---|
Beijing Wanchun Pharmaceutical Technology Ltd. | ||
BeyondSpring (HK) Limited | ||
BeyondSpring LTD. | ||
BeyondSpring Pharmaceuticals Inc. | ||
BeyondSpring Pharmaceuticals Australia PTY | ||
SEED | ||
SEED Technology | ||
Wanchun Biotechnology Limited | ||
Wanchun Biotechnology (Shenzhen) Ltd. | ||
Wanchunbulin |
BeyondSpring has 109 Twitter Followers. The number of followers has increased 10.3% month over month and increased 21.4% quarter over quarter
34
Tweets
1
Following
109
Followers
7
Tweets last 30 days
0.9
Avg. likes per Tweet
57.1%
Tweets with engagement
When was BeyondSpring founded?
BeyondSpring was founded in 2010.
Who are BeyondSpring key executives?
BeyondSpring's key executives are Lan Huang, Ramon Mohanlal and Rich Daly.
How many employees does BeyondSpring have?
BeyondSpring has 61 employees.
Who are BeyondSpring competitors?
Competitors of BeyondSpring include Omeros, Athersys and Otonomy.
Where is BeyondSpring headquarters?
BeyondSpring headquarters is located at 28 Liberty St 39th Floor, New York.
Where are BeyondSpring offices?
BeyondSpring has an office in New York.
How many offices does BeyondSpring have?
BeyondSpring has 1 office.
Receive alerts for 300+ data fields across thousands of companies